Tag: Dr Kiran Mazumdar Shaw

Customers get access to distinctive services such as genetic tests, genetic counseling, blood tests, health screening tests, antibody tests and COVID-19 RT-PCR tests

Innovation, R&D, partnership & policy support to be key growth drivers as echoed at Global Innovation Summit-2021 organized by Indian Pharmaceutical Alliance

BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets. SILS to receive ~15% stake in BBL at a post-money valuation of ~$4.9 billion......................

As per experts, the digital-enabled regulatory flexibility during the pandemic that had helped bring drugs faster to market needs to continue.....................

The launch of the initiative aims at developing a citizens’ roadmap to achieving universal health coverage. The commission will be the first participatory, country-wide report of its scale to be developed.........................

Within a month of its inception, the National Biomedical Resources Indigenization Consortium constituted by the Department of Biotechnology, has seen active engagement from several major stakeholders of Indian biomedical resources innovation community

The Centre has been set up at Syngene’s campus in Bengaluru by the Biotechnology Industry Research Assistance Council (BIRAC) and will host a state-of-the-art GLP accredited analytical laboratory. The collaboration a part of National Biopharma Mission.............

LMSAI- Harvard University collaborated with the office of Scientific Adviser to Government of India and NITI Aayog to host annual India symposium on ‘Science & Society’ on 4th April at New Delhi..................

The world’s largest gathering of the biotechnology industry witnessed a record 17,000 participants over the 4 days of the event held at Boston in the United States of America...................

Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2­positive metastatic breast cancer. The product will be marketed by the Libbs Farmaceutica........